Patent 12109305 was granted and assigned to Lyndra Therapeutics (company) on October, 2024 by the United States Patent and Trademark Office.
The invention provides gastric residence systems with specifically tailored architectures and methods for making such systems. The components of the gastric residence systems can be manufactured by three-dimensional printing or by co-extrusion. The ability to construct precise architectures for the systems provides excellent control over drug release, in vivo stability, and residence time of the systems.